Promising drug cocktail may shrink esophageal tumors before surgery
NCT ID NCT07312578
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tests whether adding two targeted drugs (nimotuzumab and camrelizumab) to standard chemotherapy before surgery can help shrink tumors in people with a certain type of esophageal cancer. About 48 adults with locally advanced but removable cancer will take part. The main goal is to see how many patients have no cancer left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of GI Oncology, Peking University Cancer Hospital,
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.